8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 20, 2017

Medizone International, Inc.

(Exact name of registrant as specified in its charter)

Nevada	2-93277-D	87-0412648
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

350 East Michigan Avenue, Suite 500 Kalamazoo, MI	49007
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (269) 202-5020

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) Resignation of Director

On June 21, 2017, Daniel D. Hoyt informed the Board of Directors (“Board”) of Medizone International, Inc. (“Company”) that he has decided to retire and will resign from the Board of Directors and retire from all positions with the Company, effective immediately. Mr. Hoyt also advised the Board that his decision is not based on any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Mr. Hoyt served as a member of the Audit and Compensation Committees of the Board.   The Board has not identified a potential replacement for Mr. Hoyt. The members of the Audit Committee as of the date of this report are Stephen Meyer, Vincent Caponi, and Dwayne Montgomery, who is the Audit Chair and the members of the Compensation Committee are Stephen Meyer, Dwayne Montgomery, and Vincent Caponi who is the Compensation Chair.  The Board has determined that each of these directors is independent under standards adopted by the Board, which conform to the standards established by the NASDAQ Stock Market and applicable regulations of the Securities and Exchange Commission (“Commission”). The Board noted that each of these directors: (1) is not an officer or employee of the Company, and (2) has no direct or indirect relationship with the Company that would interfere with the exercise of his independent judgment in carrying out his responsibilities as a director. The Board also has determined that each independent director also qualifies as “independent” as the term is used in Item 407 of Regulation S-K and as that term is defined under NASDAQ Rule 4200(a)(15). In addition, the Board believes that each member of the Audit Committee is independent as required under Section 10A(m)(3) of the Securities Exchange Act of 1934, as amended.

(e) Compensation Agreements

Modification of Stock Options – Under the terms of the Medizone International, Inc. 2014 Equity Incentive Plan (“2014 Equity Incentive Plan”), unless otherwise determined by the Board, an option holder generally may exercise an option granted under the plan following a separation of the holder’s service with the Company only if the exercise occurs within 90 days of the date of separation from the Company. The Board has determined it will modify the exercise provisions of stock options granted previously to Mr. Hoyt under the 2014 Equity Incentive Plan to permit exercise of such options for a period of up to three years from the date of Mr. Hoyt’s resignation (but not beyond the original expiration date of any such grant). No other terms or provisions of the option grants will be modified. These modifications affect two option grants made to Mr. Hoyt.  The first grant was made on April 30, 2014 for the purchase of 250,000 shares of common stock at the exercise price of $0.163 per share. This option will expire on April 30, 2019. The second grant was made on August 18, 2015 for the purchase of a total of 1,500,000 shares of common stock at an exercise price of $0.0877 per share. This option will expire on June 21, 2020, rather than the original expiration date of August 18, 2020.

Item 7.01 Regulation FD Disclosure.

On June 20, 2017, the Company issued a press release announcing it had registered to attend the Military Health System’s Vendor Day on September 27, 2017, at the Defense Medical Logistics Center on Fort Detrick in Frederick, MD.  Vendor Day presents a unique opportunity to interact directly with a large number of government agencies and to demonstrate the utility of AsepticSure.

On June 21, 2017, the Company issued a press release announcing that the AsepticSure technology had received full electrical safety approval for all models of AsepticSure. This approval means that AsepticSure has achieved compliance with applicable international safety standards.   The Company issued a second press release on June 21, 2017, announcing the retirement of director Daniel Hoyt from its Board.

Also on June 21, 2017, the Company held an investor webcast to discuss developments in its commercial strategy.  Management has prepared a slide presentation of materials for the webcast that will be accessible via the Investor Relations section of the Company’s website: http://www.medizoneint.com/investor-relations.

The press releases from June 20 and June 21, 2017 and the webcast materials are furnished (not filed) as Exhibit 99.1, Exhibit 99.2, Exhibit 99.3, and Exhibit 99.4 to this Current Report on Form 8-K pursuant to Regulation FD.  The information in this Item 7.01 shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as may be expressly set forth by specific reference in such filing or document.

Item 9.01 Financial Statements and Exhibits.

(d)  Exhibits

Exhibit Number	Description
99.1	Press Release dated June 20, 2017
99.2	Press Release dated June 21.2017
99.3	Press Release dated June 21, 2017
99.4	Investor Update (June 21, 2017)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MEDIZONE INTERNATIONAL, INC.
Date: June 22, 2017	/s/ David A. Esposito
	David A. Esposito
	Chief Executive Officer

EX-99.1

Exhibit 99.1

Medizone International Registered to Exhibit AsepticSure at the Military Health System’s Vendor Day

AsepticSure registration at the Military Health System’s Vendor Day presents opportunity to demonstrate several applications for the Department of Defense

KALAMAZOO, Mich., June 20, 2017 /PRNewswire/ -- Medizone International, Inc. (OTCQB: MZEI) announces the Company has registered to attend the Military Health System’s Vendor Day on September 27, 2017 at the Defense Medical Logistics Center on Fort Detrick in Frederick, MD.  Vendor Day presents a unique opportunity to interact directly with a large number of government agencies and to demonstrate the utility of AsepticSure.

The Military Health System Vendor Day is a cooperative venture by the military service medical logistics agencies, located on Fort Detrick in Frederick, MD. The agencies involved are: Defense Health Agency Medical Logistics Division (DHA MEDLOG), U.S. Army Medical Research and Materiel Command (USAMRMC), U.S. Army Medical Materiel Agency (USAMMA), Naval Medical Logistics Command (NMLC), Air Force Medical Operations Agency (AFMOA), U.S. Marine Corp Systems Command (MARCORSYSCOM).  The focus of the event is to assist the services’ medical logistics agencies with strategic market analysis of products and technologies that may be applicable to the austere medical environments.

“Given the broad range of applications for AsepticSure to the military, including hospital disinfection, bioterrorism countermeasures, and food handling facility disinfection, we are excited about engaging with the many agencies represented at the Military Health System’s Vendor Day,” commented David A. Esposito, Chairman and interim CEO of Medizone International. “This event builds on the work already underway to gain acceptance of AsepticSure in multiple government agencies.”

Medizone International plans to attend the event with a full display of the AsepticSure system and with several members from the sales and engineering teams to address any potential inquiries from attendees.  The Company is planning an invitation outreach to prospects in advance of the meeting to ensure maximum attendance and engagement at the exhibit booth.

About Medizone International, Inc.

Founded initially in 1986 to develop treatments for lipid-enveloped viruses, Medizone International, Inc. shifted focus in 2007 to develop a superior disinfectant technology. The company developed the AsepticSure system to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the company released its AsepticSure system for use in Canada, and several other global markets.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. 

For press information on Medizone International, please contact:John Pentony, Investor and Media RelationsMedizone International, Inc.T: 01 269-202-5020E: j.pentony@medizoneint.com

For more information, visit:http://www.medizoneint.com Email: operations@medizoneint.com

EX-99.2

Exhibit 99.2

AsepticSure® Receives Full Approval of International Electrical Safety Standards

AsepticSure approval of international safety standards clears path for global commercialization

KALAMAZOO, Mich., June 21, 2017 /PRNewswire/ -- Medizone International, Inc. (OTCQB: MZEI), the developer of AsepticSure®, a revolutionary disinfection technology that combines ozone and hydrogen peroxide to achieve unprecedented kill rates of bacteria and viral pathogens in a wide range of commercial applications including healthcare, biodefense, and public health preparedness, announced today that the Company has received full electrical safety approval for all models of AsepticSure.

The testing and approval was administered by QPS Evaluation Services, a nationally and internationally accredited independent third-party testing, certification and field evaluation body headquartered in Toronto, Canada.  The approval means that AsepticSure has achieved full compliance with the applicable international safety standards which provide a baseline requirement that must be met in order to pursue marketing in all jurisdictions, including Canada, USA, South America, EU, Asia, and the Middle East. Although Medizone will be required to apply for a separate approval in each country, compliance with these international safety standards will greatly facilitate this process.

“We are very pleased to announce that AsepticSure technology has received full approval for electrical safety,” said Dr. Michael Shannon, President and Director of Medical Affairs of Medizone International. “With respect to future marketing endeavors in North America, third-party certification of electrical products is mandated by law; without such certification, marketing would not be permitted. Approval of our AsepticSure system is a major step forward towards full commercialization.”

The achievement of full compliance with the relevant international safety standards provides the framework for detailed manufacturing specifications that will be incorporated in the Company’s expanded manufacturing plans.

About Medizone International, Inc.

Founded initially in 1986 to develop treatments for lipid-enveloped viruses, Medizone International, Inc. shifted focus in 2007 to develop a superior disinfectant technology. The company developed the AsepticSure system to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the company released its AsepticSure system for use in Canada, and several other global markets.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations

Medizone International, Inc.

T: 01 269-202-5020

E: j.pentony@medizoneint.com

For more information, visit:

http://www.medizoneint.com

Email: operations@medizoneint.com

EX-99.3

Exhibit 99.3

Medizone International Announces a Retirement from the Board of Directors

June 21, 2017 – Medizone International, Inc. (OTCQB: MZEI) (Kalamazoo, MI) the developer of AsepticSure, a revolutionary disinfection technology that combines ozone and hydrogen peroxide to achieve unprecedented kill rates of bacteria and viral pathogens in a wide range of commercial applications including healthcare, biodefense, and public health preparedness, announced today that Daniel D. Hoyt has retired from the Board of Directors.

Effective June 21, 2017, Daniel D. Hoyt will retire from the Board and all positions within the company.

“On behalf of our employees, the board, and shareholders, I want to thank Dan for his leadership and commitment to the Company. Since January 2002, Dan has been an active member of the board and he has given a full measure to support our business and our people through the amazing journey of the company,” commented David Esposito. “We wish Dan all the best as he moves into this next chapter of life with his family.”

Medizone continues to execute on plans to establish AsepticSure as a superior solution worldwide to achieve unprecedented kill rates of bacteria and viral pathogens in a wide range of commercial applications including healthcare, biodefense, and public health preparedness. The near term priority market is the United States while the Company continues to support sales and distribution channels in several other markets across the globe.

About Medizone International, Inc.

Founded initially in 1986 to develop treatments for lipid-enveloped viruses, Medizone International, Inc. shifted focus in 2007 to develop a superior disinfectant technology. The company developed the AsepticSure system to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the company released its AsepticSure system for use in Canada, and several other global markets.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

For press information on Medizone International, please contact:John Pentony, Investor and Media RelationsMedizone International, Inc.T: 01 269-202-5020 E: j.pentony@medizoneint.com

For more information, visit:www.medizoneint.com Email: operations@medizoneint.com

EX-99.4

Exhibit 99.4

    AsepticSure®  Medizone International, Inc.Investor Update – June 21, 2017  1  June 21, 2017 – 4:00 – 5:00 PM ESTToll free for North America: 1-800-681-1924Toll call outside North America: 1-303-223-4393A recording of the call will be available from 6/21/17-6/28/17:1-800-633-8284 Conference ID: 21854308  Investor Update 6/21/17 

 Safe Harbor Statement  This investor update contains forward looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the US and other markets, expansion and operations. The contents of this update should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.   2  Investor Update 6/21/17 

 Agenda  Company overviewThe Problem – The SolutionCommercial Strategy UpdateFinancialsQuestion & AnswerClosing comments   3  Investor Update 6/21/17 

 Executive Summary   Medizone International (OTCQB:MZEI) Company formed in 1986 to develop treatments for lipid enveloped virus like Hepatitis B & C and HIV/AIDSStrategic shift in 2007 to develop a disinfectant system capable of addressing a wide range of applications to minimize the transmission of diseaseCommercial systems are operational in several countries AsepticSure® is well positioned to be a superior solution worldwide within healthcare, biodefense, and public health preparednessEPA registered disinfectant system. US regulatory confirmation of disinfectant claimsPeer reviewed/published efficacy against C Difficile, MRSA, VRE and other pathogensDemonstrated efficacy to surrogates of Anthrax, Ebola, SARS and MERS-CoVIntellectual PropertyBroad patent portfolio in the US, Canada, Europe, Mexico and ChinaStrategic Intent Demonstrate market acceptance and superior performance in key addressable marketsSeek global strategic partner for co-commercialization opportunities  4  Investor Update 6/21/17 

 The Problem  Reducing the transmission of disease remains a global health priorityHealthcare facilities110% of inpatients in the U.S. contract infections from the hospital room that is manually cleaned.HAIs are the 4th leading cause of death in the U.S. and cost over $40B a year.Recent survey of hospitals with below average infection rates showed that the cost of HAIs wiped out in-patient hospital profits.Public health preparedness continues to be challenged by pandemic pathogens such as Ebola, MERS, Bird Flu, SARS & H7N9 continue Bioterrorism - The deliberate release of viruses, bacteria, toxins or other harmful agents to cause illness or death is of increasing concern across the worldExposure to healthcare waste in industries such as death care (funeral homes) and sports/fitness equipment presents another growing area for disease transmission   5  1. 2005 - California Air Resources Board’s “Indoor Air Pollution Report” and 2008 Independent studies by AMA, EPA, and CDC  Investor Update 6/21/17 

 Standard cleaningTime consuming, labor intensive and costlyProven ineffective and inconsistent  Current technologies have limited impact  6  UV TechnologyShadow effect impacts efficacyLack of regulatory approved efficacy claims  Ozone TechnologyHigh levels (500+ PPM) needed to achieve necessary kill ratesSignificant time to generate high levels and discharge upon completion  Hydrogen Peroxide TechnologyHigh concentrations (30-35%) needed to achieve necessary kill rates Harmful to electronics and room content (paint, carpet, drapes, etc.)1   1. “Paint used on the walls of one of the HPV units showed some incompatibility with the process“ Clin Infect Dis (2012) 56 (1): 27-35   Investor Update 6/21/17 

 7  The Solution - The AsepticSure System  Ease of use in a wide range of applications  The Science of Synergy  EPA validated disinfectant process: AsepticSure produced consistent kill rates across 160 runs using a nominal 1.4% Hydrogen peroxide mixture combined with 80 ppm of OzonePeer reviewed/published efficacy against C Difficile, MRSA, VRE and other pathogensDemonstrated efficacy to surrogates of Anthrax, Ebola, SARS and MERS-CoV  Investor Update 6/21/17 

 Strategic Intent: Establish AsepticSure as a superior solution worldwide to achieve unprecedented kill rates of bacteria and viral pathogens in a wide range of commercial applications including healthcare, biodefense, and public health preparednessCommercial Priorities:Regulatory ApprovalManufacturing Commercial ExecutionIntellectual Property  Commercial Strategy Update  8  Investor Update 6/21/17 

 Regulatory StatusApprovals: United States (EPA), Canada, New Zealand and ChileEPA approval (Nov 2016): AsepticSure Ozone Generator™ fogging system is for use in hospitals, clinics, food industry, sporting venues, and hotels to disinfect hard non-porous surfaces.AsepticSure Oxidative Catalyst is for use in hospitals, clinics, food industry, sporting venues, and hotels to disinfect hard non-porous surfaces.Pending FDA guidance on medical device classification Seeking approvals in priority ex-North American markets: EuropeSouth/Central America (Argentina, Brazil)AustraliaAsia (China, Malaysia)  1) Regulatory Approval   9  Investor Update 6/21/17 

 Thursday April 6, 2017 teleconference513(g) submission made on May 17, 2017 Expected response within 60 daysHighlights from the submission:Request for “confirmation that the company’s AsepticSure® (“AsepticSure® System” or the “system”) is not considered a medical device when used for general hospital disinfection purposes, and in addition, is exempt from premarket notification requirements.”Rationale for exemption: “Several devices which have been listed with FDA (class I device with pre-market exemptions) make virtually the same claims as the AsepticSure® system.”Hogan Lovells US LLP is leading the communications with the FDA  FDA Communications  10  Investor Update 6/21/17 

 Contract manufacturing support established with CogmedixCurrent FDA and EPA registered manufacturer Establishment registration number has been received by EPAPrepared to manufacture AsepticSure Generation III systemsRecent international electrical safety standards approval is being incorporated into manufacturing plansHydrogen Peroxide supplier: InnovasourceCurrent inventory of AsepticSure systemsDistributors:Canada: 2 systems South America: 3 systems Saudi Arabia: 2 systemsNew Zealand: 1 systemMedizone: 6 systems (prepped for global markets), 1 system (R&D) Ongoing R&D to enhance performance and user experience  2) Manufacturing   11  Investor Update 6/21/17 

 Addressable MarketsMarketing and sales process Technical support and customer service  3) Commercial Execution  12  Investor Update 6/21/17 

 Healthcare industryHealthcare waste exposureBio-Terrorism countermeasuresPublic health preparednessBuilding remediation  Addressable Markets  13  Investor Update 6/21/17 

 EPA registered disinfectant systemUS regulatory confirmation of disinfectant claimsCombination of oxidative compounds (O3 and H202) produces a unique mixture of free radicals with oxidation potential much higher than Ozone or Hydrogen Peroxide aloneHospital spaces and other public facilities can effectively and reliably be disinfected in less than 90 minutes TATThe reduced concentration of gases used renders AsepticSure harmless to the environment, electronic equipment, paint and treatment surfacesLethal to all pathogens including spores on all surfaces, fabrics and carpets1No lingering environmental issue affecting patient or staff health after room is disinfected   The AsepticSure Difference in Healthcare  14  1. Am J Infect Control 2011;39:873-879: Effectiveness of a novel ozone-based system for the rapid high-level disinfection of health care spaces and surfaces   Healthcare Industry  Investor Update 6/21/17 

 Efficacy testing across a wide range of pathogens including spores (C. difficile and B. subtilis)Testing occurred in test chamber and full-size laboratory room/hospital room   AsepticSure Efficacy: Am J Infection Control 2011  15  1. Am J Infect Control 2011;39:873-879: Effectiveness of a novel ozone-based system for the rapid high-level disinfection of health care spaces and surfaces   Healthcare Industry  Investor Update 6/21/17 

 16  Response to Emerging Pathogens  Klebsiella pneumonia is becoming more prevalent in many hospitals and because of its increasing antibiotic resistance it is very dangerousEfficacy tests against Klebsiella pneumoniaeCarbapenemase-resistant strain and β-lactamase resistant strain.Classified an ESKAPE pathogen, one of the leading causes of nosocomial (hospital acquired) infection in the world.Tests were performed as per client request from Chile.Results: Following a standard 40m Asepticsure treatment results in complete kill of Klebsiella pneumoniae.Log reduction: 6.31log10-6.64log10 Multiple tests with multiple samples per test.Samples are placed in multiple locations surrounding AsepticSure machine  Klebsiella pneumoniae  Healthcare Industry  Investor Update 6/21/17 

 Objectives: (A) Access potential microbiological contamination in a local funeral services mortuary (B) Conduct a pre-treatment and post-treatment assessment of AsepticSure.Process:All pretreatment surface sampling (May 9 and May 12, 2017) and treatment (May 19) were performed in the preparation room of the funeral home.All microbiology work (swab plating, incubation and identification) were performed in the Medizone Int. Microbiology Laboratory in Kingston, ON.Treatment:   AsepticSure Efficacy: The Funeral Home Study  17  Two AsepticSure machines inside the prep room running in parallel. Parameters set at 90% RH, 80ppm O3, and treat time of 60 min. Peroxide concentration was 1.4% diluted from 30% stock H2O2 with distilled H2O. Treatment process was successfully completed and post-treatment swabs were taken immediately after.   Healthcare Waste Exposure  Investor Update 6/21/17 

 Pre-treatment assessments showed significant bacterial growth in multiple locations. Plates that showed growth exhibited a variety of organisms with no one organism being predominant.Post treatment assessments showed zero growth in all locations assessed after 24h, while one bacterial colony was present at one of the 10 sample locations (top of half-wall) after 48h. Conclusion:A high level of microbial load assessed before AsepticSure treatment was no longer present after a single treatment using the AsepticSure system.Routine cleaning of preparation rooms with AsepticSure can reduce bacterial load  The Funeral Home Study: Results  18  Healthcare Waste Exposure  Investor Update 6/21/17 

 Objective: (A) Access potential microbiological contamination in routinely used sports equipment (ice hockey equipment) (B) Conduct a pre-treatment and post-treatment assessment of AsepticSure.Process:All surface sampling, treatment and microbiology work (swab plating, incubation and identification) were performed in the Medizone Int. Microbiology Laboratory in Kingston, ON.Treatment:   AsepticSure Efficacy: Athletic Equipment  19  Hockey equipment was separated in treatment room. One AsepticSure machine was used in treatment room.Parameters set at 90% RH, 80ppm O3, and treat time of 60 min. Peroxide concentration was 1.4% diluted from 30% stock H2O2 with distilled H2O. Treatment process was successfully completed and post-treatment swabs were taken immediately after.   Healthcare Waste Exposure  Investor Update 6/21/17 

 Pre-treatment assessments showed significant bacterial growth on all sports equipment items. Pre-treatment samples showed growth with a variety of organisms; no one organism being predominant.Post treatment assessments showed zero growth on all locations for all items assessed after 24hConclusion:A high level of microbial load assessed before AsepticSure treatment was no longer present after a single treatment using the AsepticSure system.Routine cleaning of athletic equipment with AsepticSure can reduce bacterial load  Athletic Equipment Study: Results  20  Healthcare Waste Exposure  Investor Update 6/21/17 

 United States Patent No. 8,636,951 – Bio-terrorism Counteraction Using Ozone and Hydrogen Peroxide (Jan 2014)Europe: Patent No. 252583B - Bio-Terrorism Counter Measures Using Ozone and Hydrogen Peroxide (June 2016)AsepticSure demonstrated bacterial spore efficacy for Anthrax surrogateB. subtilis is routinely used as an acceptable surrogate for accepted surrogate for B. anthracis in scientific literature  Bio-Terrorism Countermeasures: Anthrax  21  Bio-Terrorism Countermeasures  Investor Update 6/21/17 

 Viral efficacy studies conducted with the National Research Council-Canada (NRC Human Health Therapeutics Portfolio)Two viruses were identified by the NRC as test organisms: Adenovirus (PTG3602)Coronavirus, transmissible gastroenteritis virus (TGEV) ATCC# VR-763Allows assessment of both enveloped and non-enveloped virusesTGEV serves as a surrogate to other coronavirus such as the Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) and Sudden Acute Respiratory Syndrome Coronavirus (SARS-CoV).Established research demonstrates that susceptibility of different virus families to disinfection, filoviridae such as ebolavirus (responsible for Ebola Hemorrhagic Fever) are more susceptible to disinfection compared to coronavirus and adenovirus. AsepticSure efficacy with coronavirus and adenovirus provides scientific evidence supporting efficacy with ebolavirus.  Global Public Health: Ebola, SARS and MERS-CoV  22  Public Health Preparedness  Investor Update 6/21/17 

 Active research and development program based on initial successful trialsOverall reduction in bacterial load Mold Smoke Methamphetamine residueResidual effects from water damage  Building Remediation  23  Investor Update 6/21/17  Building Remediation 

 Lead generation:Leverage existing relationships developed by the Medizone teamUtilization of key suppliers as “commissioned” lead generatorsInvestor/shareholder relationships to support leadsTrade show attendance Social media and traditional media outreachResources:Utilize existing media content, AJIC study, and promotional materialScientific overview presentations “White paper” publications on new dataAdditional materials and website updates are in development  Marketing and Sales Process  24  Investor Update 6/21/17 

 Hospital market:Targeted implementation of Product Evaluation Program (PEP)Place instrument, consumables and service/supportPost 3-6 month demonstration, transition to purchase contractPublish resultsExpand key opinion leader network through PEP successesDefense and Public Health markets:Demonstration projects in key areas of needPartner with existing government service providersHealthcare waste exposure and building remediationPartner with leading service providers / cleaning companies   Marketing and Sales Process con’t  25  Investor Update 6/21/17 

 Medizone team in Canada can handle initial product salesOn-site training and support program to address most customersMost technical support issues can be handled remotelyDispatch support to customer as neededOptions to scale technical support and customer service:Success based expansion with placement of local technical support near major customersContract for 3rd party service and support   Technical Support and Customer Service  26  Investor Update 6/21/17 

 4) Intellectual Property  Canada: Patent No. 2735739 – Healthcare Facility Disinfection Process and System with Oxygen/Ozone (Nov. 2011)United States: Patent No. 8,551,399 – Healthcare Facility Disinfecting System (Oct 2013). Patent No. 8,636,951 – Bio-Terrorism Counteraction Using Ozone and Hydrogen Peroxide (Jan 2014). Patent No. 9,616,144 - Food-Handling Facility Disinfectant. Patent No. 8,992,829 - Sports Equipment and Facility Disinfection PatentEurope: Patent No. 252583B - Bio-Terrorism Counter Measures Using Ozone and Hydrogen Peroxide (June 2016). Healthcare Facility Disinfection System (Aug 2016)China: Patent No. ZL 201080030657.2 - Healthcare Facility Disinfection System (Nov 2015)Singapore: Patent No.176977 – Healthcare Facility Disinfecting Process and System With Oxygen/Ozone Mixture (Feb 2013)Mexico: Patent – Healthcare Facility Disinfecting Process and System With Oxygen/Ozone Mixture (Nov 2016)  27  Investor Update 6/21/17 

 Prior budgets supported through exempt private placements of equitySecure Near Term FinancingContinue with private equity offerings in the near termPreferred stock offering with strategic partnersEMA Partners outreach: Focused on securing a development, commercialization, and/or licensing partner  Financials  28  Investor Update 6/21/17 

 Agenda  Company overviewThe Problem – The SolutionCommercial Strategy UpdateFinancialsQuestion & AnswerClosing comments   29  Investor Update 6/21/17 

 Investor Update 6/21/17  30  Summary and Closing Comments  Reducing the transmission of disease remains a global health priorityAsepticSure is well positioned to be a superior solution worldwide within healthcare, biodefense, and public health functionsMedizone is continuing to expand the commercial capabilities necessary to deliver on the opportunities in the marketplace  The AsepticSure System